Editorial
Exploring the molecular and biological background of lung neuroendocrine tumours
Abstract
Lung neuroendocrine tumours (LNET) include an extremely heterogeneous group of malignancies, whose spectrum of either morphological or clinical characteristics varies from well-differentiated and indolent to poorly differentiated and fatal diseases. In the last decades, the increase in LNET incidence was probably related to an improvement in diagnostic tools (especially histology and immunohistochemistry) and lung cancer awareness, as well as to the wider diffusion of screening programs.